Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Healthcare Biotechnology
Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

9342-8530 Quebec Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by ready2go1on Jun 02, 2010 11:43am
240 Views
Post# 17150332

52 week high

52 week highI have read about the PCA3 study in at least 15 to 20 different papers this morning. Its clear that PCA3 will play a role in helping physicians determine what course to take within their patients. What was missing in all of these stories was the name Diagnocure. In the past, when news came out you would see additional interest in this site because investors were trying to find out more about CUR. 600 shares traded, give me a break. Recent news has been enough to at least push us to a new 52 week high and I still believe thats well below where we should be at this point.
     ASCO is coming up, and a poster mentioned that additional studies will be commented on at that time.
I am still looking for at least a 30% move; $1.60
     Anything that brings attention to CUR will get new investors excited about this recent news and we should see a run, until that time, its just us.
    
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities